Bausch + Lomb Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brenton L. Saunders
- Full Time Employees
- 13,500
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 520 Applewood Crescent Vaughan ON Canada L4K 4B4
- IPO Date
- May 6, 2022
- CIK
- 0001860742
- Website
- bausch.com
- Similar Companies
- Business
- Bausch + Lomb Corporation functions as a global leader in eye health, committed to enhancing and preserving vision. Its operations are structured across three distinct divisions: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health segment delivers an extensive portfolio of contact lenses, encompassing both daily disposable and planned replacement modalities, alongside essential lens care solutions. This division also provides a variety of over-the-counter eye drops, vitamins, and mineral supplements designed to address common conditions such as dry eye, allergies, and redness, including brands like Lumify and the recently acquired Blink portfolio. The Ophthalmic Pharmaceuticals division offers both branded and generic prescription medications for post-operative management and the treatment of numerous ocular conditions, including glaucoma, ocular hypertension, retinal disorders, and eye inflammation, further strengthened by the recent acquisition of Xiidra for dry eye. The Surgical division equips eye care professionals with advanced instruments and technologies for interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include sophisticated intraocular lenses and their delivery systems, phacoemulsification devices, and a comprehensive range of surgical tools, such as the enVista Envy IOL and Storz Ophthalmic Instruments. Established in 1853, the company maintains its corporate headquarters in Vaughan, Canada.
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results
Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win
Bausch + Lomb Announces Second R&D “Teach-in” Webinar
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
Bausch + Lomb Releases 2025 Sustainability Impact Report
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
Comparing Biodesix (NASDAQ:BDSX) & Bausch + Lomb (NYSE:BLCO)
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of “Hold” from Analysts
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
Bausch + Lomb Corporation (NYSE:BLCO) Short Interest Up 50.7% in March
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story
Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma